Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects|
La Vincente, S.
|Citation:||European Journal of Pain, 2011; 15(3):293-298|
|Publisher:||W B Saunders Co Ltd|
|J.L. Hay, S.F. La Vincente, A.A. Somogyi, C.B. Chapleo, J.M. White|
|Abstract:||Previous reports have demonstrated greater antinociception following administration of a buprenorphine/naloxone combination compared to buprenorphine alone among healthy volunteers. The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra-low dose naltrexone, using a range of dose ratios. A repeated-measures, double-blind, cross-over trial was undertaken with 10 healthy participants. The effects of each buprenorphine:naltrexone ratio (100:1, 133:1, 166:1, and 200:1) on cold pressor tolerance time and respiration were compared to the effects of buprenorphine only. The 166:1 ratio was associated with significantly greater tolerance time to cold pressor pain than buprenorphine alone. Minimal respiratory depression and few adverse events were observed in all conditions. These findings suggest that, as previously described with naloxone, the addition of ultra-low dose naltrexone can enhance the antinociceptive effect of buprenorphine in humans. This potentiation is dose-ratio dependent and occurs without a concomitant increase in adverse effects.|
|Keywords:||Opioids; Antinociception; Human experimental pain; Drug combinations; Buprenorphine; Naltrexone|
|Rights:||Copyright © 2010 European Federation of International Association for the Study of Pain Chapters|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.